Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any cone-rod dystrophy in which the cause of the disease is a mutation in the DRAM2 gene.
Features include sometimes findings: Nyctalopia and Photophobia. 5 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 2 | Macular atrophy, Retinal dystrophy |
Muscles | 1 | Macular atrophy |
DRAM2 encodes DNA damage regulated autophagy modulator 2 (266 aa). Plays a role in the initiation of autophagy. In the retina, might be involved in the process of photoreceptor cells renewal and recycling to preserve visual function. Highest expression in Cells EBV-transformed lymphocytes (91.5 TPM) and Spleen (70.1 TPM).
Cone-rod dystrophy 21 is associated with mutations in the DRAM2 gene on chromosome 1.
DRAM2 is classified as a druggable target with score 0.0.
Genetic testing for DRAM2 is available. Testing is considered confirmatory for diagnosis.
No clinical trials have been registered for cone-rod dystrophy 21.
30 publications have been identified in PubMed for cone-rod dystrophy 21. Research spans Basic Science / Preclinical (37%), Case Report / Case Series (23%), and Epidemiology / Natural History (23%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 11 | 37% |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 12:53 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about cone-rod dystrophy 21
7 |
23% |
Disease patterns and progression | 7 | 23% |
Research summaries | 2 | 7% |
Other research | 1 | 3% |
Clinical study results | 1 | 3% |
New treatment approaches | 1 | 3% |
Lin S (2026). [PMID: 41810893](https://pubmed.ncbi.nlm.nih.gov/41810893/). *Invest Ophthalmol Vis Sci*. [Basic Science / Preclinical]
Ekemiri K (2026). [PMID: 41760155](https://pubmed.ncbi.nlm.nih.gov/41760155/). *BMJ Open*. [Review / Meta-Analysis]
Zhou Y (2026). [PMID: 41933583](https://pubmed.ncbi.nlm.nih.gov/41933583/). *Ophthalmol Retina*. [Epidemiology / Natural History]
Parekh BJ (2026). [PMID: 41760091](https://pubmed.ncbi.nlm.nih.gov/41760091/). *Clin Exp Ophthalmol*. [Basic Science / Preclinical]
Fabard M (2026). [PMID: 41686256](https://pubmed.ncbi.nlm.nih.gov/41686256/). *Hum Genet*. [Basic Science / Preclinical]
Chou JJ (2026). [PMID: 41954843](https://pubmed.ncbi.nlm.nih.gov/41954843/). *Doc Ophthalmol*. [Case Report / Case Series]
Mousawi Z (2026). [PMID: 41126388](https://pubmed.ncbi.nlm.nih.gov/41126388/). *Ophthalmic Genet*. [Epidemiology / Natural History]
Varughese RS (2026). [PMID: 42044156](https://pubmed.ncbi.nlm.nih.gov/42044156/). *J Clin Endocrinol Metab*. [Basic Science / Preclinical]
Romo-Aguas JC (2026). [PMID: 42022048](https://pubmed.ncbi.nlm.nih.gov/42022048/). *Ophthalmol Sci*. [Epidemiology / Natural History]
Murati Calderon RA (2025). [PMID: 40718228](https://pubmed.ncbi.nlm.nih.gov/40718228/). *Cureus*. [Basic Science / Preclinical]